Innovative vaccines get EMEA panel approval

Baxter International's H5N1 flu vaccine, Celvapan, received CHMP approval last week, meaning the vaccine could become the first cell culture-based H5N1 influenza vax to hit the market. Celvapan is grown in monkey kidney cells. Sanofi Pasteur and GlaxoSmithKline currently have two egg-based vaccines on the market. The cell-based method is faster than the egg-based approach because the virus used in the vaccine does not required modification to grow in chicken eggs, Baxter tells the Center for Infectious Disease Research and Policy.

Sanofi Pasteur also snagged a CHMP recommendation for Intanza, a seasonal flu vaccine that is injected below intradermally, rather than into muscle--the first of its kind to be approved by the CHMP. The application, submitted back in February, was based on clinical trials involving more than 7,000 adult and elderly participants. In a Phase III trial, Intanza induced a stronger immune response when given intradermally than intramuscularly, Susan Watkins, a Sanofi spokeswoman tells the CIDRAP.

- view the Baxter release
- check out the Sanofi release
- read the CIDRAP for more

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

Iowa State University is working on a room-temp-stable nasal spray vaccine for COVID-19, and it recently tapped device maker Zeteo for support.

Pfizer's shot will go before an FDA expert panel on Dec. 10, with Moderna's review pegged for the 17th, Warp Speed chief Moncef Slaoui, Ph.D., said.